Highlights 

  • HUTCHMED secures renewed NRDL coverage for ELUNATE®, ORPATHYS® and SULANDA®. 
  • TAZVERIK® earns placement on China’s first Commercial Insurance Drug List. 
  • Updated NRDL takes effect on January 1, 2026, after contract renewal with the NHSA. 
  • Multi-layered reimbursement system aims to widen access to innovative oncology therapies. 
  • China’s evolving medical insurance framework supports improved affordability for high-value treatments. 

HUTCHMED Limited (NASDAQ:HCM) announced renewed inclusion of three key oncology therapies—ELUNATE®, ORPATHYS® and SULANDA®—in China’s updated National Reimbursement Drug List (NRDL), effective January 1, 2026. The renewed listing follows a contract renewal with the National Healthcare Security Administration, reflecting continued recognition of these therapies within China’s public healthcare system. 

The NRDL remains a cornerstone of pharmaceutical accessibility in China, covering a population of more than 1.3 billion people under basic medical insurance. For HUTCHMED, maintaining NRDL status is essential for strengthening nationwide access to targeted cancer therapies that address areas of considerable clinical need. 

First Commercial Insurance Drug List Adds TAZVERIK® 

Alongside the NRDL updates, TAZVERIK® has been selected for inclusion in the inaugural National Commercial Health Insurance Innovative Drug List. This new list supports coverage through commercial insurance channels such as high-limit medical plans, inclusive health initiatives (“Huiminbao”) and group health policies. 

TAZVERIK® is approved for adults with relapsed or refractory follicular lymphoma carrying EZH2 mutations who have undergone at least two prior systemic treatments. Its addition reflects growing emphasis on reimbursement pathways supporting precision oncology and advanced therapeutics outside the basic medical insurance scope. 

This dual-layer reimbursement framework—public insurance via NRDL and supplementary coverage through commercial insurance—reinforces China’s strategy to improve treatment affordability while enabling companies to expand market presence for innovative, higher-cost therapies. 

Therapies Included Under Renewed Coverage 

ELUNATE® (fruquintinib) remains listed for two indications: advanced pMMR endometrial cancer in combination with TYVYT® and metastatic colorectal cancer post-standard chemotherapy or unsuitable for anti-VEGF or anti-EGFR therapies. 
ORPATHYS® (savolitinib) continues its listing for adults with MET exon 14 skipping alteration-positive non-small cell lung cancer. 
SULANDA® (surufatinib) is renewed for the treatment of unresectable or metastatic, progressive, well-differentiated pancreatic and non-pancreatic neuroendocrine tumors. 

Together, these therapies illustrate HUTCHMED’s expanding oncology portfolio, supported by partnerships with global companies such as Eli Lilly, AstraZeneca, and Ipsen. By retaining NRDL coverage and earning new commercial insurance placement, HUTCHMED strengthens its position within China’s fast-evolving healthcare ecosystem. 

Conclusion 

HUTCHMED’s expanded reimbursement reach—through both the NRDL and the newly established Commercial Insurance Drug List—marks a meaningful step in advancing patient access to innovative cancer therapies across China. The evolving, multi-tiered insurance structure will likely accelerate the adoption of breakthrough treatments while supporting long-term growth within the domestic biopharmaceutical sector.